REG - OptiBiotix Health - Joint development agreement signed with Firmenich

OptiBiotix HealthAnnouncement

11/07/2022 07:01

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220711:nRSK9106Ra&default-theme=true

RNS Number : 9106R  OptiBiotix Health PLC  11 July 2022

OptiBiotix Health plc

("OptiBiotix" or the "Company" or "Group")

 

Joint Development Agreement signed with Firmenich

 

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing products to tackle obesity, high cholesterol and diabetes, announces that it has entered into a joint development agreement with Firmenich.  The agreement allows for collaboration between both parties to develop new products containing OptiBiotix's SweetBiotix®.

 

The agreement grants Firmenich rights to manufacture and sell SweetBiotix
products as an ingredient or in final product solutions in return for sales
based milestone and royalty payments.

 

Firmenich, the world's largest privately-owned fragrance and taste company,
was founded in Geneva, Switzerland, in 1895. It is a leading
business-to-business company specialized in the research, creation,
manufacture and sale of perfumes, flavors and ingredients, and is one of the
world's largest Stevia suppliers. Renowned for its world-class research and
creativity, as well as its leadership in sustainability, Firmenich offers its
customers superior innovation in formulation, a broad and high-quality palette
of ingredients, and proprietary technologies including biotechnology,
encapsulation, olfactory science and taste modulation. Firmenich products are
enjoyed by 4 billion consumers a day, in more than 100 international markets
and had an annual turnover of 4.3 billion Swiss Francs at end June 2021.

 

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce the
signing of a joint development agreement with Firmenich, one of the world
leaders in the taste and flavour industry.  The agreement brings together
Firmenich's research, development, manufacturing and supply chain expertise
with OptiBiotix's IP portfolio and leading expertise in the human microbiome.
We believe that this agreement will help both companies collectively bring
better science and better health to more people around the world."

 

This announcement contains inside information for the purposes of the UK
Market Abuse Regulation and the Directors of the Company are responsible for
the release of this announcement.

 

For further information, please contact:

 

 OptiBiotix Health plc                                     www.optibiotix.com (http://www.optibiotix.com/)
 Stephen O'Hara, Chief Executive  Contact via Walbrook below

 Cairn Financial Advisers LLP (NOMAD)                      Tel: 020 7213 0880
 Liam Murray / Jo Turner / Ludovico Lazzaretti

 Cenkos Securities plc (Broker)                            Tel: 020 7397 8900
 Callum Davidson / Neil McDonald
 Michael Johnson / Russell Kerr (Sales)

 Walbrook PR Ltd                                           Mob: 07876 741 001
 Anna Dunphy

 

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward
looking statements. Forward looking statements are identified by their use of
terms and phrases such as ''believe'', ''could'', "should" ''envisage'',
''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect",
''will'' or the negative of those, variations or comparable expressions,
including references to assumptions. These forward looking statements are not
based on historical facts but rather on the Directors' current expectations
and assumptions regarding the Company's future growth, results of operations,
performance, future capital and other expenditures (including the amount,
nature and sources of funding thereof), competitive advantages, business
prospects and opportunities. Such forward looking statements reflect the
Directors' current beliefs and assumptions and are based on information
currently available to the Directors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRGZGGNVRKGZZM